Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04137224

Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)

Diffuse Cutaneous Systemic Sclerosis Clinical Trial

Official title:
A Multicenter, Randomized, Open-label, Crossover, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) and IgPro10 (Intravenous Immunoglobulin, Privigen®) in Adults With Systemic Sclerosis (SSc)

Clinical Trial Summary

This is a prospective, multicenter, randomized, open-label, crossover study to investigate the safety, tolerability, and pharmacokinetics of IgPro20 in participants with diffuse cutaneous systemic sclerosis (dcSSc). The pharmacokinetic study aims to evaluate the relative bioavailability of IgPro20, and characterize pharmacokinetics of IgPro20 and IgPro10, respectively, in participants with dcSSc. Safety, tolerability, and pharmacokinetics of IgPro10 will also be evaluated.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04137224
Study type Interventional
Source CSL Behring
Contact
Status Completed
Phase Phase 2
Start date September 19, 2019
Completion date May 17, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT02161406 - A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis Phase 2
Completed NCT03222492 - Brentuximab Vedotin for Systemic Sclerosis Phase 1/Phase 2
Not yet recruiting NCT04986605 - Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis Phase 2
Completed NCT02503644 - Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis Phase 2
Recruiting NCT04781543 - A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis Phase 2
Enrolling by invitation NCT05626751 - An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc) Phase 2
Withdrawn NCT05098145 - A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis Phase 1/Phase 2
Terminated NCT04478994 - A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) Phase 1
Completed NCT03198689 - Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis Phase 2
Terminated NCT04680975 - Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis Phase 2
Completed NCT00433186 - Mycophenolate Mofetil in Systemic Sclerosis Phase 1
Terminated NCT03919799 - KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis Phase 2
Not yet recruiting NCT06152172 - CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 Phase 1
Suspended NCT04166552 - Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis Phase 2
Not yet recruiting NCT06375005 - Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis Phase 2
Recruiting NCT05270668 - Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) Phase 2
Recruiting NCT05168215 - Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease.
Completed NCT04440592 - Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis Phase 2
Recruiting NCT05149768 - Open Label Extension Study of Brentuximab Vedotin in Early dcSSc Phase 2
Withdrawn NCT04138485 - Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc) Phase 2